Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC) Meeting Abstract

  

Authors:	Beckermann, K.; Campbell, M. T.; Haas, N. B.; Ornstein, M. C.; Gao, X.; Mao, S. S.; Hammers, H. J.; George, S.; Nelson, A. A.; Gourdin, T. S.; Keshava-Prasad, H.; Hussain, A.; Hoimes, C. J.; Yan, H.; Esquibel, V.; McIntyre, G.; Geller, R. B.; Voss, M. H.; Rini, B. I.; Shah, N. J.
Abstract Title:	Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)
Meeting Title:	2023 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	41
Issue:	16 Suppl.
Meeting Dates:	2023 Jun 2-6
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2023-06-01
Language:	English
DOI:	10.1200/JCO.2023.41.16_suppl.4534
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=cin20&AN=164014110&authtype=sso&custid=s2915669&site=ehost-live&scope=site&custid=s2915669
Notes:	Meeting Abstract: 4534 -- This meeting was also held virtually -- Source: Cinahl

https://synapse.mskcc.org/synapse/works/has_related_data_chk/209440